The current invention provides a method useful for inhibiting the loss of bone using 6-hydroxy-2-(4-hydroxyphenyl)-benzo(B)-thien-3-yl-4[2-piperidin-1-ethoxyphenol]methanone hydrochloride.
|
0. 4. A method of inhibiting post-menopausal bone loss in a post-menopausal woman in need of treatment to prevent post-menopausal osteoporosis comprising administering to said woman in need of said treatment an effective amount of 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl)ethoxyphenyl]methanone hydrochloride.
1. A method of inhibiting post-menopausal bone loss in a post-menopausal woman in need of treatment to prevent or treat post-menopausal osteoporosis comprising administering to a human said woman in need thereof of said treatment an effective amount of 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B]thien-3-yl-4-[2-(piperidin-1-yl)ethoxyphenyl]methanone hydrochloride.
0. 2. The method of
|
This application is a division, of application Ser. No. 08/180,522 filed Jan. 12, 1994, now U.S. Pat. No. 5,393,763, which is a continuation of application Ser. No. 07/920,933 filed Jul. 28, 1992, now abandoned.
This invention relates to the discovery that a group of 2-phenyl-3-aroylbenzothiophenes is useful in the prevention of bone loss.
The mechanism of bone loss is not well understood, but in practical effect, the disorder arises from an imbalance in the formation of new healthy bone and resorption of old bone, skewed toward a net loss of bone tissue. This bone loss includes a decrease in both mineral content and protein matrix components of the bone, and leads to an increased fracture rate of, predominantly, femoral bones and bones in the forearm and vertebrae. These fractures, in turn, lead to an increase in general morbidity, a marked loss of stature and mobility, and, in many cases, an increase in mortality resulting from complications.
Bone loss occurs in a wide range of subjects, including post-menopausal women, patients who have undergone hysterectomy, patients who are undergoing or have undergone long-term administration of corticosteroids, patients suffering from Cushing's syndrome, and patients having gonadal anytime any time within the previous five years; patients with any undiagnosed or abnormal genital bleeding; patients with active, or a history of, thromboembolic disorders; patients who have impaired liver or kidney function; patients who have abnormal thyroid function; patients who are poor medical or psychiatric risks; or patients who consume an excess of alcohol or abuse drugs.
Patients in the estrogen treatment group receive 0.625 mg/day and the two raloxifene groups receive dosages of 200 and 600 mg/day, all groups receiving oral capsule formulations. Calcium carbonate, 648 mg tablets, is used as calcium supplement with all patients taking 2 tablets each morning during the course of the study.
The study is a double-blind design. The investigators and the patients do not know the treatment group to which the patient is assigned.
A baseline examination of each patient includes quantitative measurement of urinary calcium, creatinine, hydroxyproline, and pyridinoline crosslinks. Blood samples are measured for serum levels of osteocalcin, bone-specific alkaline phosphatase, raloxifene, and raloxifene metabolites. Baseline measurements also include examination of the uterus including uterine biopsy.
During subsequent visits to the investigating physician, measurements of the above parameters in response to treatment are repeated. The biochemical markers listed above that are associated with bone resorption have all been shown to be inhibited by the administration of estrogen as compared to an untreated individua. Raloxifene is also expected to inhibit the markers in estrogen deficient individuals as an indication that raloxifene is effective in inhibiting bone loss from the time that treatment is begun.
Subsequent longer term studies can incorporate the direct measurement of bone density by the use of a photon absorptiometry and the measurement of fracture rates associated with therapy.
Cullinan, George J., Black, Larry J.
Patent | Priority | Assignee | Title |
10251797, | Dec 29 1999 | Hill-Rom Services, Inc. | Hospital bed |
7454805, | Dec 29 1999 | Hill-Rom Services, Inc. | Hospital bed |
7926131, | Dec 29 1999 | Hill-Rom Services, Inc. | Hospital bed |
8030330, | Mar 26 1996 | Eli Lilly and Company | Benzothiophenes, formulations containing same, and methods |
8151387, | Dec 29 1999 | Hill-Rom Services, Inc. | Hospital bed frame |
8367105, | Nov 10 2004 | Teva Pharmaceutical Industries, Ltd | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
8367106, | Nov 10 2004 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
8597666, | Nov 10 2004 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
9009893, | Dec 29 1999 | Hill-Rom Services, Inc. | Hospital bed |
Patent | Priority | Assignee | Title |
4133814, | Oct 28 1975 | Eli Lilly and Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
4185108, | May 10 1977 | COLGATE-PALMOLIVE COMPANY, A CORP OF DE | Antiosteoporotic agents |
4380635, | Apr 03 1981 | Eli Lilly and Company | Synthesis of acylated benzothiophenes |
4418068, | Apr 03 1981 | Eli Lilly and Company | Antiestrogenic and antiandrugenic benzothiophenes |
4729999, | Oct 12 1984 | BCM TECHNOLOGIES, INC , 1610 WOODSTEAD COURT, SUITE 430, THE WOODLANDS, TX 77380 A CORP OF TX | Antiestrogen therapy for symptoms of estrogen deficiency |
4894373, | Oct 12 1984 | BCM TECHNOLOGIES, INC | Antiestrogens and their use in treatment of menopause and osteoporosis |
4970237, | Mar 20 1987 | Yale University | Use of clomiphene to increase bone mass in premenopausal women |
5011853, | Aug 25 1989 | Washington University; WASHINGTON UNIVERSITY, A CORP OF MO | Compounds for treatment of cholinergic neurotoxins |
5075321, | Mar 24 1987 | PENNSYLVANIA, THE UNIVERSITY OF | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
5118667, | May 03 1991 | CELTRIX PHARMACEUTICALS, INC | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
5208031, | Jun 06 1989 | KELLY, PATRICK D | Sexual lubricants containing zinc as an anti-viral agent |
5393763, | Jul 28 1992 | Eli Lilly and Company | Methods for inhibiting bone loss |
5395842, | Oct 31 1988 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
5441947, | Aug 25 1993 | NEXSTAR PHARMACEUTICALS, INC | Methods of inhibiting vascular restenosis |
5445941, | Jun 21 1993 | Eli Lilly and Company | Method for screening anti-osteoporosis agents |
5457116, | Oct 15 1993 | Eli Lilly and Company | Methods of inhibiting uterine fibrosis |
5461065, | Oct 15 1993 | Eli Lilly and Company | Methods for inhibiting endometriosis |
5462949, | Dec 21 1993 | Eli Lilly and Company | Methods of inhibiting fertility in women |
5464845, | Dec 22 1992 | Eli Lilly and Company | Methods for lowering serum cholesterol |
5468773, | Aug 25 1993 | Eli Lilly and Company | Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs |
5472962, | Nov 15 1991 | Teikoku Hormone Mfg. Co., Ltd. | Benzothiophene derivative |
5478847, | Mar 02 1994 | Eli Lilly and Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
5482949, | Mar 19 1993 | Eli Lilly and Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
5510370, | Jul 22 1993 | Eli Lilly and Company | Parathyroid hormone and raloxifene for increasing bone mass |
5534527, | Jul 28 1992 | Eli Lilly and Company | Methods for inhibiting bone loss by treating with aroylbenzothiophenes and estrogen |
5567713, | Jun 24 1993 | Eli Lilly and Company | Hypoglycemic agents |
5591753, | Jan 28 1994 | Eli Lilly and Company | Combination treatment for osteoporosis |
5624940, | Dec 14 1993 | Eli Lilly and Company | Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof |
5629425, | Sep 19 1994 | Eli Lilly and Company | Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thi ophene |
5641790, | Mar 02 1994 | Eli Lilly and Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
5646137, | Jan 28 1994 | Eli Lilly and Company | Combination treatment for osteoporosis |
5731327, | Apr 26 1995 | Eli Lilly and Company | Synthesis of 3-[4-(2-aminoethoxy)benzoyl]-2-aryl-6-hydroxybenzo [b]thiophenes |
5747510, | Mar 02 1994 | Eli Lilly and Company | Pharmaceutical unit dosage formulations |
5811120, | Mar 02 1994 | Eli Lilly and Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
5972383, | Mar 02 1994 | Eli Lilly and Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
6087378, | Oct 13 1998 | Eli Lilly and Company | Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome |
6096781, | Nov 14 1997 | Eli Lilly and Company | 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome |
6156786, | Nov 14 1997 | Eli Lilly and Company | 2-aryl-3-aroylbenzo[b]thiophenes useful for the treatment of estrogen deprivation syndrome |
6395769, | Nov 14 1997 | Eli Lilly and Company | 2-arylbenzo[b]thiophenes useful for the treatment of estrogen deprivation syndrome |
6458811, | Mar 26 1996 | Eli Lilly and Company | Benzothiophenes formulations containing same and methods |
6713494, | Aug 28 1996 | Eli Lilly and Company | Amorphous benzothiophenes, methods of preparation and methods of use |
EP62505, | |||
EP68563, | |||
EP605193, | |||
EP68563, | |||
GB2097788, | |||
NO304924, | |||
WO9310113, | |||
WO9310741, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Feb 27 2003 | Eli Lilly and Company | (assignment on the face of the patent) | / |
Date | Maintenance Fee Events |
Mar 20 2007 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
Feb 07 2009 | 4 years fee payment window open |
Aug 07 2009 | 6 months grace period start (w surcharge) |
Feb 07 2010 | patent expiry (for year 4) |
Feb 07 2012 | 2 years to revive unintentionally abandoned end. (for year 4) |
Feb 07 2013 | 8 years fee payment window open |
Aug 07 2013 | 6 months grace period start (w surcharge) |
Feb 07 2014 | patent expiry (for year 8) |
Feb 07 2016 | 2 years to revive unintentionally abandoned end. (for year 8) |
Feb 07 2017 | 12 years fee payment window open |
Aug 07 2017 | 6 months grace period start (w surcharge) |
Feb 07 2018 | patent expiry (for year 12) |
Feb 07 2020 | 2 years to revive unintentionally abandoned end. (for year 12) |